危险系数
医学
置信区间
生物标志物
肺癌
肿瘤科
免疫组织化学
内科学
人口
病理
肺
谷氨酸羧肽酶Ⅱ
细胞
癌症
总体生存率
比例危险模型
抗原
癌症研究
生存分析
上皮细胞粘附分子
中国人口
作者
Marina Chiara Garassino,Myung‐Ju Ahn,Markus Schick,Ansh Kapil,Luis G Paz-Ares,Aaron Elliott Lisberg,Melissa Lynne Johnson,Maurice Pérol,Toshio Shimizu,Rebecca Suk Heist,Alexander I. Spira,Isamu Okamoto,Nicolas Girard,Robin Cornelissen,Elvire Pons Tostivint,Min Hee Hong,Ricardo F. Zwirtes,Rachel A. Chiaverelli,Marlon Cezar Rebelatto,Matthew S. Sung
标识
DOI:10.1038/s41591-026-04716-9
摘要
Datopotamab deruxtecan (Dato-DXd)-a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate-has demonstrated efficacy in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ± actionable genomic alterations. However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC. We developed TROP2 quantitative continuous scoring (QCS)-a fully supervised computational pathology approach that quantifies TROP2 expression in individual NSCLC cells and subcellular components from immunohistochemistry-stained slides. Using QCS to determine TROP2 expression at the tumor cell membrane and cytoplasm, normalized membrane ratio (NMR) was developed (ratio of membrane relative to membrane + cytoplasmic TROP2) in the biomarker-evaluable population of patients with advanced NSCLC in the TROPION-PanTumor01 study (n = 115). The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the biomarker-evaluable population (n = 352) of the TROPION-Lung01 trial. Association with clinical outcomes was assessed. Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by biomarker status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive biomarker for Dato-DXd.
科研通智能强力驱动
Strongly Powered by AbleSci AI